Pulmonary perfusion with oxygenated blood or custodiol HTK solution during cardiac surgery for postoperative pulmonary function in COPD patients: a trial protocol for the randomized, clinical, parallel group, assessor and data analyst blinded Pulmonary Protection Trial by Katrine B Buggeskov et al.
TRIALS
Buggeskov et al. Trials 2013, 14:30
http://www.trialsjournal.com/content/14/1/30STUDY PROTOCOL Open AccessPulmonary perfusion with oxygenated blood or
custodiol HTK solution during cardiac surgery for
postoperative pulmonary function in COPD
patients: a trial protocol for the randomized,
clinical, parallel group, assessor and data analyst
blinded Pulmonary Protection Trial
Katrine B Buggeskov1*, Jørn Wetterslev2, Niels H Secher3, Lars W Andersen4, Thomas Jonassen5
and Daniel A Steinbrüchel6Abstract
Background: Five to thirty percent of patients undergoing cardiac surgery present with chronic obstructive
pulmonary disease (COPD) and have a 2- to 10-fold higher 30-day mortality risk. Cardiopulmonary bypass (CPB)
creates a whole body systemic inflammatory response syndrome (SIRS) that could impair pulmonary function.
Impaired pulmonary function can, however, be attenuated by pulmonary perfusion with oxygenated blood or
custodiol HTK (histidine-tryptophan-ketoglutarate) solution.
Methods/Design: The Pulmonary Protection Trial (PP-Trial) randomizes 90 patients undergoing CPB-dependent
cardiac surgery to evaluate whether pulmonary perfusion with oxygenated blood or custodiol HTK solution reduces
postoperative pulmonary dysfunction in COPD patients. Further, we aim for a non-randomized evaluation of
postoperative pulmonary function after transcatheter aortic-valve implantation (TAVI). The primary outcome
measure is the oxygenation index measured from anesthesia induction to the end of surgery and until 24 hours
after anesthesia induction for a total of six evaluations.
Discussion: Patients with COPD may be impaired by hypoxemia and SIRS. Thus, prolonged recovery and even
postoperative complications and death may be reflected by the degree of hypoxemia and SIRS. The limited sample
size does not aim for confirmatory conclusions on mortality, cardiovascular complications or risk of pneumonia and
sepsis, but the PP-Trial is considered an important feasibility trial paving the road for a multicenter confirmatory trial.
Trial registration: ClinicalTrials.gov: NCT01614951.
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Pulmonary dysfunction is a complication of cardiac sur-
gery with cardiopulmonary bypass (CPB) and yet a pre-
operative pulmonary function test (PFT) is not performed
routinely although lung function appears to be an inde-
pendent predictor of both morbidity and mortality [1].
Five to thirty percent of patients undergoing cardiac sur-
gery present with chronic obstructive pulmonary disease
(COPD), and patients with moderate to severe COPD, in-
cluding a fifty percent reduction in diffusion capacity,
demonstrate a 2- to 10-fold higher 30-day mortality
risk [1-3].
Depending on the preoperative lung function, pulmon-
ary dysfunction varies from only a short need of mechanical
ventilation to fever, productive cough, pulmonary edema,
respiratory failure, and consequent prolonged ICU - length
of stay (ICU-LOS) and, in the most severe cases, adult
respiratory distress syndrome (ARDS) with a mortality rate
of approximately 50% [4-6].
The etiology of pulmonary dysfunction after CPB-
dependent cardiac surgery is multifactorial [4,5,7-9]. How-
ever, contact of blood with artificial surfaces creates a
whole body systemic inflammatory response syndrome
(SIRS), lung ischemia and reperfusion injury with increases
in immunologic mediators and CPB-induced non-physio-
logic laminar perfusion, including release of endotoxins
from the splanchnicus area, are considered reasons for
postoperative pulmonary dysfunction [4,5,7-9].
In clinical trials for patients with a preoperative nor-
mal lung function, the reduction in PF ratio (PF = PaO2/
FiO2) and increase in immunologic mediators are atte-
nuated by pulmonary perfusion with oxygenated blood
[10,11] or custodiol HTK (histidine-tryptophan-ketoglu-
tarate) solution [12].
The custodiol HTK solution is similar to the chemical
composition of extracellular fluid, including a low potassium
concentration, and is used for flushing donor liver, kidney,
heart, lung, and pancreas prior to organ harvesting [13].
Alternatively to CPB- dependent aortic valve re-
placement (AVR), transcatheter aortic-valve implan-
tation (TAVI) represents a procedure during which the
aortic valve is replaced via inguinal access without the use
of CPB. Procedural stress, including the inflammatory
response is, therefore, expected to be reduced. Whether
the TAVI procedure preserves lung function remains,
however, unknown.
This trial evaluates whether pulmonary perfusion with
oxygenated blood or custodiol HTK solution reduces post-
operative pulmonary dysfunction after CPB-dependent
cardiac surgery in patients with COPD. Further, we aim
for a non-randomized evaluation of postoperative pulmon-
ary function after TAVI in COPD patients compared to
COPD patients undergoing CPB-dependent cardiac sur-
gery, with or without pulmonary perfusion.Aims
This trial assesses 1) the effect of pulmonary perfusion with
oxygenated blood or custodiol HTK solution during CPB
on postoperative arterial oxygenation in COPD patients
undergoing cardiac surgery, and 2) postoperative arterial
oxygenation after TAVI compared to CPB-dependent car-
diac surgery, with or without pulmonary perfusion in
COPD patients.
Methods/Design
The trial is designed as an open, assessor and data analyst
blinded, randomized clinical trial on patients with COPD
undergoing cardiac surgery. The patients will be rando-
mized 1:1:1 to pulmonary perfusion with oxygenated
blood or custodiol HTK solution during CPB, while
patients who are not provided with selective pulmonary
perfusion during CPB and those undergoing TAVI serve
as control groups. The randomization procedure will be
stratified according to the severity of COPD since we ex-
pect a relation between the responses to the interventions
and the severity of COPD.
Patients having a TAVI are currently randomized to
either CPB-dependent aortic valve replacement or TAVI
(ClinicalTrials.gov: NCT01057173) and therefore will
patients undergoing TAVI not be randomized for the Pul-
monary Protection Trial (PP-Trial) because they do not
receive any intervention. Patients undergoing TAVI serve,
however, as controls for the intervention groups in the
PP-Trial and will be enrolled when approximately half of
the patients are randomized to pulmonary perfusion with
oxygenated blood or custodiol HTK solution, or control.
The distribution of the severity of COPD in the TAVI
patients will be attempted to be identical with the distri-
bution in the randomized groups.
Inclusion criteria
1. The patients included in the trial undergo either Coronary artery bypass graft (CABG)
 AVR
 CABG + AVR
 TAVI
2. The preoperative PFT indicates COPD defined as
FEV1/FVC ≤70% [14].
3. Informed consent is obtained from each patient.
Exclusion criteria
 Age <18 years.
 Previous surgery of the heart or lungs.
 Previous thoracic exposure to radiation.
 Preoperative heart failure (ejection fraction <20%).
Figure 1 Randomization. Step 1 and 2 in randomization of a patient to intervention with, in this example, pulmonary perfusion with
oxygenated blood during CPB generated by a web-based system following successful screening and stratification of a patient (all inclusion
criteria fulfilled, no exclusion criteria fulfilled, informed consent obtained). CPB, cardiopulmonary bypass.
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systolic blood pressure <100 mmHg.
 Tracheal intubation before surgery.
 Treatment with antibiotics for pneumonia.
 Hemodialysis.
 Patients who are pregnant or nursing.
Randomization
Staff at the trial site have 24-hour access to an
internet-based randomization system developed by
The Copenhagen Trial Unit (CTU) to allow for con-
cealed allocation and intervention with pulmonary
perfusion with blood or pulmoplegia versus no such
intervention [Figure 1].
The allocation sequence is computer-generated with a
variable block size that is unknown to the investigators.
Randomization of the patients is stratified into two groups
according to preoperative lung function: 1) mild COPD
and 2) moderate, severe or very severe COPD [Figure 2].
We expect a 50/50 distribution of the patients into the
two groups since there are only a few or no patients oper-
ated who present with severe or very severe COPD.
Each patient will be provided with a unique patient-
and randomization number.
Primary outcome measure
The primary outcome measure will be the oxygenation
index (OI) that is measured from anesthesia induction,
to the end of surgery and until 24 hours after induction
for a total of six evaluations.
Secondary outcome measures
 Oral tracheal intubation after surgery (hours).
 ICU-LOS after surgery (hours).
 Number of pneumonia and ventilator-associated
pneumonia (VAP) 90 days after randomization.
 Bleeding and number of blood transfusion products
administered during surgery and within the first 24
hours after surgery.
 Number of reoperations due to hemorrhage.
 Decrease in thoracic electrical impedance in
reflection of accumulation of extra-vascular lungFigure 2 Classification of COPD. The limit is set out in international recowater (EVLW) during surgery and within the first
24 hours thereafter.
 Number of hyperkalemic episodes requiring
treatment with a diuretic during surgery and within
24 hours thereafter.
 Increase in plasma markers of inflammation (IL-6,
MCP-1 and so on).
 Cell and differential counts in bronchoalveolar
lavage fluid (BALF).
 Number and degree of activated alveolar
macrophages (AMACs) in BALF.
 T-cells measurement and differentiation in BALF.
 Alveolar membrane thickness and surface area by
open lung biopsy before and after CPB to indicate
intracellular fluid accumulation.
 Degree of uncoupling the oxidative phosphorylation
in musculus transversus abdominis and pulmonary
tissue mitochondria.
 Number of tracheotomies 90 days after
randomization.
 Hospitalization stay after surgery (days).
 Number of readmissions with a ventilation-related
problem within 90 days after randomization.
 Reduction in PFT 90 days after randomization.
 30- and 90-day mortality.
Anesthesia, CPB, and lung protection
Anesthesia is induced with fentanyl (10 μg/kg), propofol
(1 to 2 mg/kg) and cisatracurium (0.1 mg/kg) and main-
tained with sevoflurane (0.5% to 3%) and continuous infu-
sion of remifentanil (15 to 30 μg/kg/hour). One peripheral
vein, one radial artery and the internal jugular vein are
cannulated. The ventilation mode is volume controlled
with positive end-expiratory pressure (PEEP) set at 5
mmHg and lung recruitment is performed after CPB.
After heparinization (350 IU/kg, ACT >480 sec), nor-
mothermic CPB (36.5 to 37.0°C bladder temperature) is
initiated as follows: in the ascending aorta an angled arter-
ial cannula is placed (DLP 24 FR, Medtronic, Minneapolis,
Minnesota, USA) and the right atrial appendage is provided
with a two-stage venous cannula (36/46 FR, Medtronic). A
membrane oxygenator (Capiox RX25, Terumo, Tokyo,
Japan) and a roller pump (Stockert S5, Sorin Group,mmendations [15,16]. COPD, chronic obstructive pulmonary disease.
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The arterial line includes a 40-μm filter (AL06, Pall, Port
Washington, NY, USA). Pump flow is 2.4 L/minute/m2
body surface area. Mean arterial pressure is kept between
40 and 60 mm Hg.
In group I, the main pulmonary artery is provided with
a straight arterial cannula (14 FR DLP, Medtronic), the
aorta is cross-clamped, cardioplegia administered and pul-
monary perfusion initiated at 300 to 400 ml/minute from
the CPB circuit. We aim to maintain a pulmonary flow
equaling about 10% of the patient’s total flow resulting in
an overall flow rate of 110% until cross clamp release. The
blood returning from the pulmonary circuit is drained to
the venous reservoir via a left atrial vent (VT-53218,
CalMed Laboratories, Costa Mesa, CA, USA). During
CPB the lungs are not ventilated and that applies also to
groups II and III.
The pulmonary perfusion pressure (PPP) is monitored
online via the pulmonary cannula. We aim to maintain a
PPP equal to the patient's baseline pulmonary artery mean
pressure (PAMP) and not to exceed 20 mmHg.
In the event of lack of volume, the pulmonary perfusion
is stopped and subsequently resumed when the needed
volume is re-established.
Before aortic cross-clamp release the pulmonary perfu-
sion is terminated and the pulmonary cannula removed.
In group II, pulmoplegia with 2 L 4°C custodiol HTK
solution is performed after cardioplegia via a pulmonary
artery cannula. The PPP is monitored similarly to group
I and used to guide the infusion rate. The surgical pro-
cedure can continue during the pulmoplegia that takes
about 8 to 10 minutes. The blood and solution returning
from the pulmonary circuit to the left atrium is sucked
and filtrated by a cell saver. The custodiol HTK solution
is discarded and the remaining red blood cells are
returned to the patient.
In group III, standard CPB is performed as described.
For groups I, II and III the residual blood in the CPB cir-
cuit is retransfused to patients after CPB. In case of
excesses, fluid ultrafiltration (BC60 plus, Maquet, Wayne,
NJ, USA) is performed during rewarming.
In group IV, TAVI is performed according to cur-
rent guidelines at Rigshospitalet (ClinicalTrials.gov:
NCT01057173).
Blood samples
In all patient groups, blood samples for inflammatory indi-
cators are collected from the pulmonary artery catheter:
(1) after anesthesia induction; (2) at CPB start; (3) after
declamping of the aorta; (4) 10 and 20 minutes after CPB;
(5) at the end of surgery; (6) 120, 240, and 360 minutes
after CPB; and (7) 24 hours post anesthesia induction. A
total of 3 ml of blood is placed in ethylenediaminetetraa-
cetate coated tubes, immediately centrifuged (or kept onice for a maximum of 60 minutes) for 10 minutes at 1,800
rpm and cooled to 4°C. Plasma is extracted and stored in
polypropylene test tubes at −80°C until assayed. Blood
samples and measurements for determination of the dif-
ferent oxygenation values are obtained at time points 1, 4,
6 and 7.
Thoracic electrical impedance is measured at time
points 1 through 7.
Bronchoalveolar lavage
Two bronchoalveolar lavages (BAL) are performed using
a flexible video 6 mm bronchoscope after induction of
anesthesia and following termination of CPB [17]. Lido-
caine gel (20 mg/g) is applied to the tip of the broncho-
scope before insertion and the bronchoscope is wedged
into a segment of the medial part of the right middle
lobe. Sterile isotonic saline at 37°C is instilled in four
aliquots of 60 ml, immediately aspirated (low suction
<100 mmHg), and pooled into a sterile container on ice
to obtain a BAL specimen.
Pooled non-filtered BALF is centrifuged in tubes con-
taining a carrier protein (1% BSA in PBS) at 3,500 rpm at
4°C for 15 minutes and the supernatants are kept at −80°C
until analysis. Total and differential cell counts are ana-
lyzed within 60 minutes from pooled non-filtered and
non-centrifuged BALF.
Oxygenation index and alveolar–arterial oxygen gradient
Blood samples for arterial gas analysis are processed im-
mediately using a calibrated blood gas system (Radiom-
eter, ABL 825, Broenshoej, Denmark). The oxygenation
index is:
OI ¼ FiO2 MPAW
PaO2
where FiO2 is the fractional concentration of oxygen in
the inspired air and MPAW is the mean airway pressure.
We also calculate the pulmonary membrane diffusing
capacity for oxygen (DmO2) as:
DmO2 ¼ PAO2PaO2⋅
Q CaO2CvO2ð Þ
where PAO2 is the partial pressure of alveolar oxygen,
PaO2 the partial pressure of arterial oxygen,
⋅
Q cardiac
output, CaO2 the oxygen concentration of arterial blood
from the left atrium and CvO2 the oxygen concentration
of venous blood from the pulmonary artery.
Lung and muscle biopsies
Two open lung biopsies will be obtained. One from lin-
gula at the commencement of CPB and one from the right
middle lobe before weaning from CPB. The lung tissue
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formaldehyde for histological examination; 2) will be sub-
merged immediately into liquid nitrogen and stored in
polypropylene test tubes at −80°C until assayed by PCR;
and 3) will be placed in relaxing medium (as described
below for the muscle biopsy) until assayed for mitochon-
dria function.
When the thorax is opened a biopsy will be obtained
from the musculus transversus abdominis and placed in
relaxing medium (10 mM Ca-EGTA buffer, 0.1 μM free cal-
cium, 20 mM imidazole, 20 mM taurine, 50 mMK-MES,
0.5 mM DTT, 6.56 mM MgCl2, 5.77 mM ATP, 15 mM
phosphocreatine, pH 7.1) at 2 to 4°C. Individual fiber bun-
dles will be separated with forceps and then permeabilized
for 30 minutes in 3 ml of ice-cold relaxing medium with
saponin (50 μg·ml-1). Muscle bundles will be measured for
wet weight and placed into the respirometer (Oxygraph-2
k, Oroboros Instruments, Innsbruck, Austria) containing
a medium including EGTA (0.5 mM), MgCl2·6H2O (3
mM), K-lactobionate (60 mM), taurine (20 mM), KH2P04
(10 mM), HEPES (20 mM), sucrose (110 mM), BSA (1 g/l)
at a pH of 7.1 and assayed for mitochondria function.
Criteria for extubation and discharge from the ICU
The oral tracheal intubation time is defined as from the
end of surgery until extubation in the ICU in whole hours.
The patient is extubated when the following criteria are
met:





 PEEP ≤5 cm H2O
 Ventilation rate 10 to 12 L/minute
 Bleeding from chest drains ≤200 ml/time
 Blader temperature ≥36°C
 The patient is awake and alert, pain free,
hemodynamically stable with sufficient cough
reflexes and swallowing movements.
On the following morning the patient is discharged
from the ICU to the surgical ward if there is:
 Uncomplicated anesthesia and recovery process in
the ICU.
 Blood loss ≤500 ml in patients with a preoperatively
normal Hgb.
Blinding
Patients and personnel in intensive care, recovery room,
and ward are blinded to which group the patient is ran-
domized. The experimental setup, however, does notallow blinding of the surgeons, anesthesiologists, and
other staff members within the operating room. It will be
emphasized that the involved staff does not report or dis-
close the randomization, for example, it will not be
entered into the patient’s file.
Blood samples, BALF, and lung biopsies will be labeled
with a unique patient number (starting 101) and personnel
carrying out analyses will be blinded to which group the
patient is randomized. Several of the other outcome vari-
ables cannot, however, be blinded but represent objective
measures established at a fixed time. Decision makers on
when to extubate a patient or whether FiO2 and other ven-
tilator settings should be changed will be blinded to the
allocation of the patient.
The patient's case report form (CRF) will be completed
by the project coordinator or other personnel in accor-
dance with the trial master file (TMF) list of tasks. The
CTU will conduct blinded, double entry of the CRF data
and blinded statistical analyses in which the intervention
groups are coded as A, B, C, and D will be performed.
Based on this analysis two blinded conclusions will be
established: firstly assuming that groups A + B represent
the intervention groups will be compared with data from
groups C + D representing the control groups; and sec-
ondly the reverse scenario is assumed. Hereafter, and only
then, will the groups be unmasked.Serious adverse reactions
Serious adverse reactions (SARs) described with the use of
the custodiol HTK solution include electrolyte imbalance
(hyponatremia, hypocalcemia, hyperkalemia, hypermagne-
semia) and fluid overload [13]. Such manifestations can
also be related to CPB but if they manifest, they will be
recorded in the CRF and after an independent statistician
has evaluated the data reported to the Ethics Committee
and Danish Health & Medicines Authority. Furthermore,
such events will be compared among the patients included
in the two active trial groups. Yet, we consider that the
amount of infused custodiol HTK solution is small (max-
imum 100 ml). Under all circumstances the Sponsor will
provide a yearly report to the Ethics Committee and the
Danish Health & Medicines Authority.
Suspected unexpected serious adverse reactions
(SUSARs) will be defined as SARs not described in the
summaries of product characteristics for custodiol HTK
solution [13]. SUSARs will be reported by the trial site
investigator to the Sponsor within 24 hours. The
Sponsor ensures that all information on SUSARs that are
fatal or life-threatening will be recorded and reported to
the Danish Health & Medicines Authority and Dr. Franz
Köhler Chemie GmbH as soon as possible and no later
than within seven days after the sponsor becomes aware
of such side effects.
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& Medicines Authority within 15 days after the Sponsor is
informed of such events. When reporting SUSARs the
e-form on the Danish Health & Medicines Authority’s
website is used.
Patients in the pulmonary perfusion group will also be
followed for 24 hours during which, for example, bleeding,
the number of blood transfusions, and the need for reo-
peration due to hemorrhage is recorded.
For patients undergoing cardiac surgery, the total time
in the operating theatre is locally 6 to 8 hours, the time
requiring mechanical ventilation is 10 to 12 hours, and
the patients spend 7 to 10 days in hospital. All such data
will be recorded in the CRF and reported to the Ethics
Committee and Danish Health & Medicines Authority if
it deviates markedly.
Events directly related to the surgery and events directly
related to the normal course for this type of patient will be
recorded but not reported as incidents. These events are:
apoplexia cerebri, transient cerebral ischemia, acute myo-
cardial infarction, heart failure, pericardial tamponade,
pericardial effusion, arrhythmias, deep vein thrombosis,
pneumothorax, emphysema, pleural effusion, pneumonia,
subcutaneous emphysema, mediastinitis, anemia, pain,
nausea, generalized weakness, constipation, esophagitis,
ileus, gastric ulcer, acute liver damage, acute tubulointersti-
tial nephropathy, sepsis, wound infection and others.
Safety
Discontinuation of the trial for an individual patient:
Patients will be withdrawn from the interventions in the
PP-Trial protocol if SARs or SUSARs occur.
Discontinuation of the whole trial: For a SUSAR or in
case there is raised suspicion that a SAR may be related to
the experimental treatment, this will be reported to the
Ethics Committee and the Danish Health & Medicines
Authority. There will, however, not be any interim ana-
lyses during the trial and the trial will not be terminated
before the estimated sample size has been reached due to
apparently beneficial effects of the interventions.
Yet, the trial will be terminated if results from other
trials within the period of the trial show clear benefit or
harm with one or more of the interventions.
Patients’ withdrawal
Patients who are withdrawn from the PP-Trial trial proto-
col (see Safety) will be followed and analyzed the same as
the remaining patients. Patients may withdraw their
informed consent to participate in the trial at any time.
The patients who withdraw their consent to participate in
the trial will be asked for permission to obtain data for the
primary outcome measure. If the patient declines, how-
ever, no data will be collected. All randomized patients
will be reported, and all data available with consent will beused in the analyses. If appropriate, multiple imputation
will be used [18]. If there are patients with missing data
for the primary outcome measure, new patients will be
randomized to obtain the full sample size.
Patients who are transferred to another ICU will be
followed up for the primary outcome measure and all
other assessable secondary outcome measures.
Sample size estimation
Previously, a randomized clinical trial of pulmonary per-
fusion with oxygenated blood versus standard CPB [11]
and a randomized clinical trial with custodiol HTK solu-
tion pulmoplegia versus standard CPB [12] has been per-
formed. The primary outcome measure for these trials
was the PF ratio defined as PF = PaO2/FiO2.
For the trial of pulmonary perfusion with oxygenated
blood versus standard CPB the standard deviation (SD)
for the PF ratio was 50 mmHg and the mean difference
was 55 mmHg. For the trial of custodiol HTK solution
pulmoplegia versus standard CPB, the SD for the PF ratio
was 110 mmHg and the mean difference was 150 mmHg.
This experiment has theoretically six possible compari-
sons with randomization to three groups and a secondary
control group represented by TAVI. However, for practical
reasons five comparisons will be performed as this trial,
based on the sample size estimation, does not include
enough patients to perform a comparison between pul-
monary perfusion with oxygenated blood and custodiol
HTK solution. With multiple comparisons the risk of a
type 1 error increases and to limit the family wise error
rate to 0.05, we set the significance level to α = 0.01 for
each of the five comparisons planned. The power 1 - β
(β being the risk of a type 2 error set to 0.20) of each com-
parison is set to 80%.
Using the Dupont & Plummer power and sample size
calculator [19], the required number of patients to detect
or reject a relevant mean difference of 50 mmHg between
pulmonary perfusion with oxygenated blood versus stan-
dard CPB is estimated at 30 patients for each group. The
required number of patients to detect or reject a relevant
mean difference of 150 mmHg in the PF ratio during the
postoperative period between pulmonary perfusion with
custodiol HTK solution versus standard CPB is estimated
at 14 patients for each group. We have therefore chosen
to set N = 4 × 30 = 120.
If the PF ratios in the above two interventions both prove
to be superior to standard CPB, it is to be expected that
the difference in the PF ratio between pulmonary perfusion
with oxygenated blood or custodiol HTK solution will be
less than the differences between the PF ratio of the two
interventions and the PF ratio of the standard CPB. With a
fixed N = 120, pulmonary perfusion with oxygenated blood
versus custodiol HTK solution pulmoplegia yields a power
of 67% to detect or reject a mean difference of 55 mmHg
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assessed there from. To obtain a power of 80% for the
detection or rejection of a mean difference of 55 mmHg in
comparison with pulmonary perfusion with oxygenated
blood or custodiol HTK solution, with a risk of type 1 error
of 1%, would require 52 patients in each group.
Statistical analysis plan
The differences between the groups according to the pri-
mary outcome measure of OI, as mentioned measured six
times during the postoperative period, will be tested with
a mixed-effects model. For other continuous outcomes we
will use analysis of variance (ANOVA). If the ANOVA is
significant, a Student's t-test for unpaired groups will be
used to locate deviating values. For the mixed-effects
model and the variance analyses P-values less than 0.05
are considered to be statistically significant. For the
Student’s t-test, P-values less than 0.01 are considered to
be statistically significant. The difference between groups
of the frequency of patients with binary outcomes includ-
ing frequency of patients with one or more adverse events
will be tested with a Chi2 test.
Trial results will be analyzed according to the modified
intention to treat principle [17]. Post-randomization exclu-
sion will be allowed only for patients not undergoing CPB
dependent heart surgery. Further, per-protocol analyses
will be performed excluding patients with major protocol
violations defined as: 1) patients who were randomized to
an intervention but did not receive any intervention; 2)
patients who received an incorrect intervention; or 3)
patients randomized to standard CPB who received pre-
operative pulmonary perfusion; and 4) patients who vio-
lated one or more inclusion or exclusion criteria.
With data missing on more than 5% of the patients
(12 patients) a complete case analysis will be made, pro-
vided that the missing data can be assumed to be at ran-
dom and that Little’s test is not significant. If missing
data cannot be assumed to be at random and Little’s test
is significant, multiple imputations will be performed as-
suming missing data at random [20].
Data registration
Data will be registered in the CRF from patient notes
(source) by trial or clinical personnel under the supervi-
sion of the trial investigators. From the CRFs the trial
database (CTU) will be established by double data entry
to minimize errors when converting data from paper to an
electronic database. The following data will be registered:
Pre-operation characteristics (all obtained from hospital
notes):
 National identification number, sex, ethnicity,
age at randomization, height in cm, weight in kg,co-morbidities (previous cardiac or lung surgery,
previous thoracic irradiation, previous admission
for heart failure, myocardial infarction or
stroke, asthma, COPD Y/N, chronic treatment
for arterial hypertension, hypercholesterolemia
or diabetes Y/N, cancer Y/N, and habitual
p-creatinine and estimated glomerular filtration
rate (eGFR)).
 A detailed heart and lung status including results
from coronary angiography, echocardiography
and PFT.
 Results from pre-operation blood samples (standard
laboratory values), alcohol and medication status.
Per-operative data:
 Heart rate, mean arterial blood pressure, PAMP,
left arterial pressure, central venous pressure, PPP
during perfusion with oxygenated blood or
custodiol HTK solution, cardiac rhythm, central
venous oxygen saturation, cardiac output, PEEP,
mean airway pressure, fraction of inspired oxygen
and so on.
 Operating, perfusion and aortic cross clamp time,
thoracic impedance, end surgical fluid status, arterial
and mixed venous blood gases post induction, at
start of CPB, at aortic cross-clamp release, and post
CPB until 24 hours post anesthesia induction.
Post-operative data:
 Cardiac status (arrhythmias, myocardial infarction,
persisted pacemaker need, direct current conversion,
treated pericardial effusion, maximum levels of
creatine kinase muscle and brain (CKMB) and
troponin T (TnT), coronary angiography and/or
angioplasty), neurologic status (stroke, convulsions,
comatose >24 hours), respiratory status (total
intubation time, reintubation, ventilator associated
pneumonia, pneumothorax, pneumonia, treated
pleural effusion) with blood gases two, four and six
hours post CPB and the next morning after surgery,
hemorrhage (amount 24 hours post operation in
milliliters, amount in milliliters and type of blood
transfusion), gastrointestinal status (ulcus, ileus,
intestinal ischemia), renal status (renal replacement
therapy, maximal creatinine).
 The total hospitalization time in days, ICU-LOS in
hours, readmission to ICU, the need of and reason
for reoperation, blood samples (standard laboratory
values) and medication status on discharge from the
Department of Cardiothoracic Surgery and to where
the patient is discharged (home, local hospital or an
organ specific department).
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 Cardiac status (New York heart association (NYHA)
and canadian cardiovascular society (CSS)
classification, arrhythmias, myocardial infarction,
persistent pacemaker need, heart failure, peripheral
ischemia, venous thrombosis), sternal problems
(loose, pain, resuturing), respiratory status (PFT,
admission to hospital due to cough, shortness of
breath and/or sputum, exacerbation of COPD,
pneumonia), medication status.
 Total days of dialysis-dependency (any form of
filtration or hemodialysis) summarized at day 90
from hospital notes or registries.
 Dialysis-dependency at day 90 defined as need of
renal replacement therapy after day 90 post-
randomization.
 Survival status obtained from hospital or civil registries.
 If the patient is deceased, date of death.
During the entire PP-Trial:
 SARs (Y/N for every day) including severe bleeding
or serious allergic reactions defined as urticaria
associated with worsened circulation (20% decrease
in blood pressure or 20% increase in vasopressor
dose), increased airway resistance (20% increase in
the peak pressure on the ventilation, clinical stridor
or bronchospasm).
1/2 and 1 year after randomization:
 Survival status obtained from hospital or civil registries.
Data handling and retention
Data will be handled according to the Danish Data Protec-
tion Agency. All original records (including consent forms,
CRFs, SUSAR reports and relevant correspondence) will
be retained at the trial site or CTU for 15 years to allow
inspection by the good clinical p ractice (GCP) unit at the
Copenhagen University or local authorities. The trial data-
base will be anonymized if requested by the authorities.
Monitoring
The trial will be externally monitored (the GCP unit at
University of Copenhagen) to GCP standards according
to the EU directive 2001/20. Trial site investigators will
provide access to source data according to the Clinical
Trial Agreement.
Ethics
The trial will adhere to the Helsinki Declaration II and the
national laws of Denmark. The PP-Trial is approved by
the Committees on Biomedical Research Ethics of TheCapital Region of Denmark protocol no. H-1-2012-024,
the Danish Medicines Agency journal no. 2012024017
(EudraCT no. 2011-006290-25, protocol code 4141), the
Danish Data Protection Agency journal no. 2011-41-7051
and registered at ClinicalTrials.gov NCT01614951.
Patients will be enrolled only after informed consent.
No biological material will be collected for the trial,
thus no bio-bank will be formed.
Data analyses and publications
An independent statistician will perform the data analysis
prior to breaking the randomization code. Based on these
masked analyses of the primary and secondary outcome
measures two abstracts with conclusions will be written
by Katrine Bredahl Buggeskov. The randomization code
will then be opened and a final manuscript written inclu-
ding the correct of the two pre-made abstracts. The
manuscript will be submitted (to one of the major clinical
journals) regardless of the results and the trials reported
according to the Consolidated Standards of Reporting
Trials (CONSORT) statement from 2010 [21]. Authorship
will be granted depending on personal input according to
the international committee of medical journal editors
(ICMJE) definitions. All investigators will be acknowl-
edged. Funding sources will have no influence on data
handling, analysis or writing of the manuscript. Sib studies
will be allowed if approved by the steering committee.
Timeline
2010 to 2011: Applications for funding, ethical committees
and medicines agencies, development of CRF and data
management tools and development of monitoring plan.
2012 to 2014: Inclusion of patients.
Early 2015: Data analyses, writing and submission of
the main manuscript for publication.
Collaborators
The CTU has developed the internet based randomization
system and the trial database together with the steering
committee.
The GCP unit at University of Copenhagen has deve-
loped the monitoring plan and coordinated monitoring.
Finances
The trial is funded by the Lundbeck Foundation, Nord-
Medica, Aase & Ejnar Danielsens Fond and resources at
trial sites. The funding sources have no influence on the
trial design or data collection, management, analysis or
reporting. The patients are covered by local insurance at
the trial site.
Perspective
The project combines interdisciplinary expertise in cardio-
vascular surgery, cardiothoracic anesthesiology, and cell
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risk cardiac surgical group because of their preoperative
reduced lung function. There are currently no methods to
mitigate the deterioration of lung function after cardiac
surgery in this patient group. In the PP-Trial we use
sophisticated intensive care and innovative monitoring in
the form of invasive and non-invasive monitoring, clinical
physiological examinations and biochemical, cell bio-
logical, immune-histochemical and histological analyses.
It is expected that trial results can contribute in innova-
tive ways to: 1) a better understanding of pulmonary physi-
ology, hemodynamics, and the role of lung inflammation
during cardiac surgery; 2) a randomized clinical trial by
intervention with pulmonary perfusion with oxygenated
blood or custodiol HTK solution to improve the post-
operative oxygenation ability for cardiac surgical patients
with COPD; 3) develop a template for classification of car-
diac surgical patients as low or high immunologic respon-
ders, making it possible to individualize patient treatment
with a focus on reducing the CPB-triggered inflammatory
response deleterious effects on the organs; and 4) to deter-
mine if the respiratory failure in TAVI patients is mainly
due to an inflammatory response or to pump failure.
The results may be used as a precursor to a larger rando-
mized multicenter trial and in other patient groups with,
for example,a major surgical trauma, expected long CPB-
time (extracorporeal membrane oxygenation treatment),
and in severe sepsis/sepsis shock where our lung protective
modalities may be able to reduce the pulmonary driven
part of the immunologic response, and thereby diminish
the degree of pulmonary failure and reduce mortality.Discussion
The PP-Trial will provide important data on the use of
pulmonary perfusion with oxygenated blood or custodiol
HTK solution in patients with COPD undergoing cardiac
surgery. An alternative strategy could be cooling of rele-
vant organs leading to an overall reduced cell turnover [5].
The PP-Trial has its limitations due to its inherent ex-
ploratory nature with the primary outcome of OI being a
surrogate outcome. However, it is important to address the
fact that patients with COPD, and especially patients with
moderate to severe COPD, may be functionally incapaci-
tated by hypoxemia, SIRS and prolonged recovery, and
even an increased number of postoperative complications
and death may be reflected by the degree of hypoxemia
and SIRS. The sample size does not aim for confirmatory
conclusions on the effect on important patient outcomes,
such as mortality, cardiovascular complications, and risk
of pneumonia and sepsis, which need a large trial with a
low risk of bias, but the PP-Trial is considered an impor-
tant feasibility trial paving the road for a possible prag-
matic multicenter confirmatory trial.Trial status
The trial was registered 6 June 2012. Patients are en-
rolled from the Department of Cardiothoracic Surgery at
Rigshospitalet, University of Copenhagen, Denmark. We
expect to include two patients per week (holidays
excluded) and to finish inclusion in 1 ½ years.
Presently (1 February 2013), 425 patients have been
screened and 36 randomized.
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